Boji Medicine: Subsidiary "Qingzhi Soft Ointment" has been approved for clinical trials of drugs.

Boji Pharmaceutical announced that its wholly-owned subsidiary, Guangzhou Boji New Drug Clinical Research Center Co., Ltd., has obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the "Qingzhi Ointment" that it applied for. The drug is named Qingzhi Ointment, indicated for knee osteoarthritis, and classified as a traditional Chinese medicine class 1.1. The notice number is 2025LP02962.